TY - JOUR
T1 - Mitotic checkpoint regulator RAE1 promotes tumor growth in colorectal cancer
AU - Kobayashi, Yuta
AU - Masuda, Takaaki
AU - Fujii, Atsushi
AU - Shimizu, Dai
AU - Sato, Kuniaki
AU - Kitagawa, Akihiro
AU - Tobo, Taro
AU - Ozato, Yuki
AU - Saito, Hideyuki
AU - Kuramitsu, Shotaro
AU - Noda, Miwa
AU - Otsu, Hajime
AU - Mizushima, Tsunekazu
AU - Doki, Yuichiro
AU - Eguchi, Hidetoshi
AU - Mori, Masaki
AU - Mimori, Koshi
N1 - Funding Information:
OITA Cancer Research Foundation (grant number: JP20cm0106475h0001); Takeda Science Foundation; Japan Agency for Medical Research and Development (grant number: JP20cm0106475h0001); Japan Society for the Promotion of Science (grant number: 19H03715, 19K09176, 20H05039, 20K08930). This research used the super-computing resource provided by the Human Genome Center, The Institute of Medical Science, The University of Tokyo (http://sc.hgc.jp/shirokane.html). We thank K. Oda, M. Kasagi, M. Sakuma, T. Fukuda, M. Murakami, N. Mishima, T. Kawano, M. Oshiumi, and M. Utou for their technical assistance and Dr Tyler Lahusen for helpful comments and English proofreading. This work was supported in part by the following grants and foundations: Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Science Research (grant numbers 19K09176, 19H03715, 20H05039, and 20K08930); OITA Cancer Research Foundation; AMED under Grant Number JP20cm0106475h0001; and Takeda Science Foundation.
Funding Information:
This research used the super‐computing resource provided by the Human Genome Center, The Institute of Medical Science, The University of Tokyo ( http://sc.hgc.jp/shirokane.html ). We thank K. Oda, M. Kasagi, M. Sakuma, T. Fukuda, M. Murakami, N. Mishima, T. Kawano, M. Oshiumi, and M. Utou for their technical assistance and Dr Tyler Lahusen for helpful comments and English proofreading. This work was supported in part by the following grants and foundations: Japan Society for the Promotion of Science (JSPS) Grant‐in‐Aid for Science Research (grant numbers 19K09176, 19H03715, 20H05039, and 20K08930); OITA Cancer Research Foundation; AMED under Grant Number JP20cm0106475h0001; and Takeda Science Foundation.
Funding Information:
OITA Cancer Research Foundation (grant number: JP20cm0106475h0001); Takeda Science Foundation; Japan Agency for Medical Research and Development (grant number: JP20cm0106475h0001); Japan Society for the Promotion of Science (grant number: 19H03715, 19K09176, 20H05039, 20K08930).
Publisher Copyright:
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
PY - 2021/8
Y1 - 2021/8
N2 - Microtubules are among the most successful targets for anticancer therapy because they play important roles in cell proliferation as they constitute the mitotic spindle, which is critical for chromosome segregation during mitosis. Hence, identifying new therapeutic targets encoding proteins that regulate microtubule assembly and function specifically in cancer cells is critical. In the present study, we identified a candidate gene that promotes tumor progression, ribonucleic acid export 1 (RAE1), a mitotic checkpoint regulator, on chromosome 20q through a bioinformatics approach using datasets of colorectal cancer (CRC), including The Cancer Genome Atlas (TCGA). RAE1 was ubiquitously amplified and overexpressed in tumor cells. High expression of RAE1 in tumor tissues was positively associated with distant metastasis and was an independent poor prognostic factor in CRC. In vitro and in vivo analysis showed that RAE1 promoted tumor growth, inhibited apoptosis, and promoted cell cycle progression, possibly with a decreased proportion of multipolar spindle cells in CRC. Furthermore, RAE1 induced chemoresistance through its anti–apoptotic effect. In addition, overexpression of RAE1 and significant effects on survival were observed in various types of cancer, including CRC. In conclusion, we identified RAE1 as a novel gene that facilitates tumor growth in part by inhibiting apoptosis and promoting cell cycle progression through stabilizing spindle bipolarity and facilitating tumor growth. We suggest that it is a potential therapeutic target to overcome therapeutic resistance of CRC.
AB - Microtubules are among the most successful targets for anticancer therapy because they play important roles in cell proliferation as they constitute the mitotic spindle, which is critical for chromosome segregation during mitosis. Hence, identifying new therapeutic targets encoding proteins that regulate microtubule assembly and function specifically in cancer cells is critical. In the present study, we identified a candidate gene that promotes tumor progression, ribonucleic acid export 1 (RAE1), a mitotic checkpoint regulator, on chromosome 20q through a bioinformatics approach using datasets of colorectal cancer (CRC), including The Cancer Genome Atlas (TCGA). RAE1 was ubiquitously amplified and overexpressed in tumor cells. High expression of RAE1 in tumor tissues was positively associated with distant metastasis and was an independent poor prognostic factor in CRC. In vitro and in vivo analysis showed that RAE1 promoted tumor growth, inhibited apoptosis, and promoted cell cycle progression, possibly with a decreased proportion of multipolar spindle cells in CRC. Furthermore, RAE1 induced chemoresistance through its anti–apoptotic effect. In addition, overexpression of RAE1 and significant effects on survival were observed in various types of cancer, including CRC. In conclusion, we identified RAE1 as a novel gene that facilitates tumor growth in part by inhibiting apoptosis and promoting cell cycle progression through stabilizing spindle bipolarity and facilitating tumor growth. We suggest that it is a potential therapeutic target to overcome therapeutic resistance of CRC.
UR - http://www.scopus.com/inward/record.url?scp=85107851905&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107851905&partnerID=8YFLogxK
U2 - 10.1111/cas.14969
DO - 10.1111/cas.14969
M3 - Article
C2 - 34008277
AN - SCOPUS:85107851905
SN - 1347-9032
VL - 112
SP - 3173
EP - 3189
JO - Cancer Science
JF - Cancer Science
IS - 8
ER -